Answers are grounded in this paper and cite their sources.
These results demonstrate the feasibility and durability of TFR following frontline nilotinib and emphasize the importance of sustained DMR for TFR.
No takes yet. Share an insight, caveat, or question.
Ross et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: